Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
PurposeAgents that inhibit sodium glucose co-transporter 2 (SGLT2), including canagliflozin and dapagliflozin, become available for the treatment of Chinese patients with type 2 diabetes mellitus (T2DM). This study assessed the economic outcomes of canagliflozin 100 mg versus dapagliflozin 10 mg in...
Saved in:
Main Authors: | Xingyun Hou (Author), Xu Wan (Author), Bin Wu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Canagliflozin and risk of amputation in patients with type 2 diabetes
by: T. M. Bukatina, et al.
Published: (2018) -
Emerging treatments in type 2 diabetes: focus on canagliflozin
by: Rosiak M, et al.
Published: (2014) -
Canagliflozin: a novel treatment option for type 2 diabetes
by: Dietrich E, et al.
Published: (2013) -
Cost-Effectiveness Analysis of Dapagliflozin Plus Standard Treatment for Patients With Type 2 Diabetes and High Risk of Cardiovascular Disease in China
by: Kaiyu Huang, et al.
Published: (2022) -
Comparison of the efficacy of dapagliflozin and linagliptin in the treatment of type 2 diabetes patients with normal body mass index and poor metformin monotherapy
by: Mingli He, et al.
Published: (2024)